Medicine and Dentistry
Alzheimer's Disease
9%
Autoradiograph
7%
Biochemical Recurrence
12%
Biodistribution
18%
Biological Marker
7%
Carbon 11
22%
Chemokine Receptor
39%
Chemokine Receptor CXCR4
10%
Choline
10%
Diagnosis
16%
Disease
12%
Dosimetry
16%
Ex Vivo
6%
Fluorine-18
70%
Fluorodeoxyglucose F 18
18%
Gallium 68
100%
Gamma Chemokine
9%
Immunohistochemistry
9%
In Vitro
11%
Indium 111
8%
Integrin
20%
Iodine 125
7%
Lutetium 177
18%
Lymph Node
7%
Magnetic Resonance Imaging
11%
Malignant Neoplasm
14%
Metastatic Carcinoma
10%
Molecular Imaging
22%
Multiple Myeloma
8%
Neoplasm
67%
Octreotide
11%
Pharmacokinetics
8%
Polyethylene Terephthalate
65%
Positron Emission Tomography
76%
Positron Emission Tomography - Magnetic Resonance Imaging
10%
Positron Emission Tomography-Computed Tomography
63%
Prostate Cancer
61%
Prostate Specific Antigen
12%
Prostate Specific Membrane Antigen
51%
Prostatectomy
8%
Radiation Therapy
12%
Radioactive Tracer
60%
Radioligand
10%
Radiopharmaceutical Agent
9%
Radiosurgery
8%
Receptor
8%
Somatostatin Receptor
8%
Standardized Uptake Value
13%
Tetraxetan
10%
Tumor Xenograft
6%
Keyphrases
125I
12%
18F-fluorodeoxyglucose (18F-FDG)
13%
18F-fluorothymidine
9%
18F-labeled
28%
68Ga-pentixafor
37%
After Injection
9%
Alzheimer's Disease
12%
Amyloid Plaques
11%
Angiogenesis
9%
Biodistribution
25%
C-X-C Chemokine Receptor Type 4 (CXCR4)
66%
Chelator
19%
Chemokine Receptor
9%
Chemokine Receptor CXCR4
11%
CXCR4 Expression
18%
Endoradiotherapy
13%
Gallium-68
59%
High Affinity
12%
Hybrid Radio
14%
IC50
9%
Immunohistochemistry
9%
Integrin
31%
Integrin Expression
13%
Kidney
14%
Liver
11%
Lutetium-177 (177Lu)
31%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
9%
Molecular Imaging
22%
Octreotide
15%
Pentixafor
13%
PET Imaging
23%
PET Tracer
9%
PET-MRI
12%
Pharmacokinetics
14%
Positron Emission Tomography
69%
Positron Emission Tomography-computed Tomography (PET-CT)
59%
Preclinical Evaluation
16%
Prostate Cancer
36%
Prostate-specific Antigen
69%
Radiochemical Yield
10%
Radioligand Therapy
10%
Radiopharmaceuticals
19%
Radiotracer
10%
Standardized Uptake Value
19%
SUVmax
12%
Technetium-99m
9%
Theranostics
12%
Tracer Uptake
10%
Tumor
48%
Tumor Uptake
14%
Pharmacology, Toxicology and Pharmaceutical Science
Amino Acid
7%
Amyloid Protein
7%
Biochemical Recurrence
6%
Biodistribution
19%
Carbon 11
14%
Castration Resistant Prostate Cancer
9%
Chelating Agent
10%
Chemokine Receptor
10%
Clinical Trial
5%
Disease
8%
Dosimetry
11%
Fluorine 18
69%
Gallium 68
51%
IC50
9%
Integrin
25%
Iodine-125
11%
Lipophilicity
6%
Lutetium 177
25%
Malignant Neoplasm
14%
Neoplasm
61%
Octreotide
9%
Opiate Receptor
6%
Pharmacokinetics
18%
Polyethylene Terephthalate
60%
Prostate Cancer
28%
Prostate Specific Antigen
7%
Prostate Specific Membrane Antigen
35%
Radioisotope
9%
Radioligand
15%
Radiopharmaceutical Agent
17%
Receptor
20%
Somatostatin Receptor
6%
Technetium 99m
9%
Tetraxetan
16%
Tracer
44%
